BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 33197518)

  • 1. Effect of vitamin D on malignant behavior of non-small cell lung cancer cells.
    Songyang Y; Song T; Shi Z; Li W; Yang S; Li D
    Gene; 2021 Feb; 768():145309. PubMed ID: 33197518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
    Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
    Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression.
    Xiong L; Tan B; Lei X; Zhang B; Li W; Liu D; Xia T
    IUBMB Life; 2021 Sep; 73(9):1092-1102. PubMed ID: 34033225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
    Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
    Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproliferative Activity of Carnosic Acid is Mediated via Inhibition of Cell Migration and Invasion, and Suppression of Phosphatidylinositol 3-Kinases (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
    Zhao L; Zhang J; Fan Y; Li Y
    Med Sci Monit; 2019 Oct; 25():7864-7871. PubMed ID: 31631173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of endoplasmic reticulum stress promotes autophagy and apoptosis and reverses chemoresistance of human small cell lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Yu XS; Du J; Fan YJ; Liu FJ; Cao LL; Liang N; Xu DG; Zhang JD
    Oncotarget; 2016 Nov; 7(47):76827-76839. PubMed ID: 27765907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxysafflor yellow A inhibited lipopolysaccharide-induced non-small cell lung cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT/mTOR and ERK/MAPK signaling pathways.
    Jiang M; Zhou LY; Xu N; An Q
    Thorac Cancer; 2019 Jun; 10(6):1319-1333. PubMed ID: 31055884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
    Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
    Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
    Wang J; Wang HY; Shen Y; Liang D; Wang HY; Zhang SQ; Cao YX; Cao L
    Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
    Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
    Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Berberine targets KIF20A and CCNE2 to inhibit the progression of nonsmall cell lung cancer via the PI3K/AKT pathway.
    Wang Q; Wu H; Wu Q; Zhong S
    Drug Dev Res; 2023 Aug; 84(5):907-921. PubMed ID: 37070571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
    J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.